MGB Biopharma Nominated and Shortlisted for Scottish Enterprise Life Sciences Award
MGB Biopharma announced that it has been nominated and shortlisted for the 2015 Scottish Enterprise Life Sciences Annual Award for “Investment of the Year”.
The awards, for which there are six categories this year, recognise excellence in companies and individuals who are making a significant contribution to the life sciences industry. MGB Biopharma is one of three shortlisted finalists in the “Investment of the Year” category. Judging criteria includes the significance of the investment to the sector and improving the Company’s ability to get products to the market faster, shows an advancement on technology and an innovative approach to investment. The winners will be announced at the Scottish Life Sciences Annual Dinner in February 2015.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “It is a great honour to be nominated and shortlisted for such an eminent award. We have made great progress to ensure we are well funded to advance the development of our lead antibacterial MGB-BP-3, with continued support from our existing investors and the recent Biomedical Catalyst award. We believe that our novel candidate, which originated from the University of Strathclyde, has the potential to transform antimicrobial resistance to bring true novelty to the market for over a decade.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.